Why is end-of-life spending so high? Evidence from cancer patients
Pasireotide for malignant insulinoma
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
This gives hope': A third COVID-19 vaccine dose can boost protection for organ transplant recipients | Science | AAAS
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | NEJM
Frontiers | miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) - Annals of Oncology
Frontiers | miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
Phase II organâ•'preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry | npj Breast Cancer
Clinical effectiveness of seasonal influenza vaccine among adult cancer patients
Pharmaceuticals | Free Full-Text | Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy
Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy
WP2: Resilience Definition and operationalization
Collaterals
A genome‐wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi‐kinase inhibitors in hepatocellular carcinoma cells - Sofer - 2022 - The FASEB Journal - Wiley Online Library
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast can
Cetuximab intensifies cisplatin-induced testicular toxicity
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
Durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: Three-month follo
Cancers | Free Full-Text | Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
